Modafinil
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Modafinil: From Narcolepsy/Excessive Daytime Sleepiness to Insomnia
Summary in One Sentence
Modafinil is a wakefulness-promoting agent (eugeroic), currently with approved indications focused on narcolepsy, residual sleepiness from obstructive sleep apnea (OSA), shift work sleep disorder (SWSD), and other "wakefulness-promoting" indications. The TxGNN model predicts it may be effective for insomnia, with a score as high as 99.85%, but among the 29 clinical trials and 19 literature reports collected, the vast majority discuss modafinil/armodafinil use for treating "sleepiness and fatigue secondary to other diseases," rather than as a direct treatment drug for insomnia — this is a signal of possibly opposite pharmacological direction that requires careful interpretation.
Quick Overview
| Item | Content |
|---|---|
| Approved Indications | No marketed/authorized record in New Zealand; based on the mechanism-of-action description attached to the evidence package, known approved uses include narcolepsy, residual sleepiness from OSA, and shift work sleep disorder (SWSD) |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L4 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction (Possibly) Unreasonable?
Currently, detailed modafinil mechanism-of-action (MOA) data is not available for review (Data Gap). However, according to the mechanism-association analysis attached within the evidence package, modafinil's core pharmacology involves dopamine reuptake inhibition and activation of the hypothalamic orexin/histamine arousal pathway, with a pharmacological effect of "promoting wakefulness," with clinically known uses including narcolepsy, residual sleepiness from OSA, and SWSD.
The pathophysiological mechanism of insomnia is opposite in direction — it is difficulty initiating or maintaining sleep, and clinically requires sedative/sleep-promoting drugs, not wakefulness-promoting agents. In other words, the pharmacological action of modafinil and the treatment needs of insomnia are directionally contradictory.
Reviewing the 29 trials and 19 literature reports included in this assessment, only 1 trial (NCT01091974, association level B) directly mentions insomnia in its title, and in that trial armodafinil was used to address post-chemotherapy "fatigue," with the insomnia component actually managed by CBT-I (cognitive behavioral therapy for insomnia), with the drug serving only an auxiliary role. The remaining trials mostly focused on narcolepsy, OSA, bipolar affective disorder, Parkinson's disease gait/sleepiness, post-chemotherapy fatigue, and other topics, with weak direct treatment evidence for insomnia. This high-score prediction is likely a directional misjudgment caused by the TxGNN knowledge graph clustering modafinil with the "sleep disorders" node ensemble, and should be regarded as a false signal requiring manual review rather than a directly viable drug repurposing lead.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00124384 | Phase 4 | Completed | 40 | Only trial with primary insomnia patients as subjects, evaluating modafinil alone or combined with CBT-I on daytime function and insomnia severity |
| NCT01091974 | Phase 2 | Completed | 138 | CBT-I combined with or without armodafinil for post-chemotherapy insomnia and fatigue in breast cancer patients; armodafinil primarily addressed fatigue rather than insomnia itself |
| NCT01019187 | Phase 2 | Completed | 226 | Larger scale enrollment with design similar to above (CBT combined with or without armodafinil) for managing post-chemotherapy insomnia and fatigue in cancer survivors |
| NCT02552303 | N/A | Completed | 39 | Armodafinil and/or CBT-I for insomnia patients with comorbid sleep apnea (OSA) |
| NCT01011218 | Phase 2 | Completed | 70 | Pilot study on insomnia management in breast cancer patients, with some arms combined with armodafinil 150 mg/day |
| NCT01080807 | Phase 4 | Completed | 385 | Armodafinil for excessive sleepiness related to shift work sleep disorder (SWSD), not insomnia treatment |
| NCT01305408 | Phase 3 | Completed | 399 | Armodafinil as adjunctive treatment for severe depressive episodes in bipolar I disorder |
| NCT06404099 | Phase 2 | Active, not recruiting | 361 | RECOVER-SLEEP platform trial evaluating multiple interventions for post-COVID (PASC) sleep disorders |
| NCT06404086 | Phase 2 | Completed | 830 | Another branch of the same RECOVER-SLEEP platform trial as above |
| NCT00233090 | Phase 2 | Terminated | 21 | Modafinil vs placebo for post-traumatic brain injury fatigue, not insomnia treatment, small sample and already terminated |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18729534 | 2008 | Review | Drugs | Evidence review of modafinil approved and investigational uses, covering sleepiness-related clinical trial evidence |
| 24312590 | 2013 | Systematic Review/Meta-analysis | PLoS One | Meta-analysis of modafinil efficacy for fatigue and excessive sleepiness related to neurological diseases |
| 39535843 | 2024 | Review | Expert Opin Pharmacother | Pharmacological and non-pharmacological management of sleep disorders in Parkinson's disease |
| 27010071 | 2016 | Systematic Review | Parkinsonism Relat Disord | Systematic review and meta-analysis of pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease |
| 22021174 | 2011 | Guideline/Evidence-Based Review | Mov Disord | MDS Evidence-Based Medicine Review: Update on treatment of non-motor symptoms in Parkinson's disease |
| 18805301 | 2008 | Review | Rev Neurol | Review of narcolepsy with cataplexy, including sleep maintenance insomnia as one of its accompanying symptoms |
| 17181377 | 2006 | Review | Drugs | Review of disease burden and treatment approaches for shift work sleep disorder (SWSD) |
| 20166851 | 2010 | Review | Expert Opin Emerg Drugs | Review of emerging therapeutic drugs for narcolepsy and related disorders |
| 24272458 | 2014 | Unclassified | Neurotherapeutics | Treatment of sleep disorders in Parkinson's disease, noting that optimal treatment for insomnia remains unclear |
| 15824337 | 2005 | Unclassified (randomized placebo-controlled double-blind trial design) | Neurology | Randomized controlled trial of modafinil for multiple sclerosis-related fatigue |
New Zealand Market Information
Modafinil is currently Not marketed in New Zealand, with no authorization license records found (total_licenses = 0), and therefore cannot provide information on dosage forms, product names, or approved indications.
Safety Considerations
Currently, no product package insert warnings, contraindications, or drug-drug interaction data for modafinil could be found (TFDA package insert analysis is a Blocking-level data gap, DDI query yielded no results).
Please refer to the complete product package insert for safety considerations.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism-association analysis within the evidence package has already clearly indicated that modafinil is a wakefulness-promoting agent with a pharmacological direction opposite to insomnia treatment needs; among the clinical trials and literature included in this assessment, only very few directly involve insomnia treatment, and most serve as auxiliary/combined roles rather than primary efficacy evidence. Although this prediction score is high (99.85%), it is likely a directional misjudgment caused by knowledge graph clustering effects, with an evidence level of only L4, insufficient to support progression to the next stage of evaluation.
If advancement is to proceed, the following should be supplemented:
- Complete modafinil mechanism-of-action (MOA) data to clarify whether any sedative/sleep-promoting pharmacological pathways exist
- Complete TFDA/manufacturer package insert warnings, contraindications, and drug-drug interaction data (currently a Blocking-level data gap)
- Perform knowledge graph pathway tracing (path explanation) for this TxGNN prediction to confirm whether the "insomnia" node connection reflects real clinical scenarios (such as "insomnia as a comorbid symptom" rather than "insomnia as primary treatment")
- If this direction is to be further evaluated, additional manual review by sleep medicine specialists is needed to exclude the possibility of directional misjudgment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.